Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer-A report of two cases

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 111-113

  Ochi, Nobuaki ^a   Yamane, Hiromichi ^a   Yamagishi, Tomoko ^a   Takigawa, Nagio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Brain metastasis; Non small cell lung cancer; Pemetrexed

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; PEMETREXED;

ADULT; AXILLARY LYMPH NODE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MONOTHERAPY; NEEDLE BIOPSY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875279952     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.010     Document Type: Letter

References (17)

1. Schwer A.L., Gaspar L.E. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 2006, 8:180-186.
2. Ortuzar W., Hanna N., Pennella E., Peng G., Langer C., Monberg M., et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 2012, 13:24-30.
3. Edelman M.J., Belani C.P., Socinski M.A., Ansari R.H., Obasaju C.K., Chen R., et al. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:110-116.
4. Hanauske A.R., Chen V., Paoletti P., Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001, 6:363-373.
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Gaspar L.E., Chansky K., Albain K.S., Vallieres E., Rusch V., Crowley J.J., et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005, 23:2955-2961.
7. Chikamori K., Kishino D., Takigawa N., Hotta K., Nogami N., Kamei H., et al. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer 2009, 65:74-79.
8. Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007, 25:2306-2312.
9. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011, 21:107-112.
10. Dai H., Chen Y., Elmquist W.F. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 2005, 315:222-229.
11. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011, 8:344-356.
12. Barlesi F., Gervais R., Lena H., Hureaux J., Berard H., Paillotin D., et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 2011, 22:2466-2470.
13. Bearz A., Garassino I., Tiseo M., Caffo O., Soto-Parra H., Boccalon M., et al. Activity of Pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010, 68:264-268.
14. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
15. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
16. D'Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
17. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J.-L., Bidoli P., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13:247-255.